References
- Kolditz M, Tesch F, Mocke L, et al. Burden and risk factors of ambulatory or hospitalized CAP: a population based cohort study. Respir Med. 2016;121:32–38.
- Lee E, Kim CH, Lee YJ, et al. Annual and seasonal patterns in etiologies of pediatric community-acquired pneumonia due to respiratory viruses and Mycoplasma pneumoniae requiring hospitalization in South Korea. BMC Infect Dis. 2020;20(1):132.
- Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020;46(2):315–328.
- Ho J, Ip M. Antibiotic-resistant community-acquired bacterial pneumonia. Infect Dis Clin North Am. 2019;33(4):1087–1103.
- Guo S, Mao X, Liang M. The moderate predictive value of serial serum CRP and PCT levels for the prognosis of hospitalized community-acquired pneumonia. Respir Res. 2018;19(1):193.
- Wang Z, Huo B, Wu Q, et al. The role of procalcitonin in differential diagnosis between acute radiation pneumonitis and bacterial pneumonia in lung cancer patients receiving thoracic radiotherapy. Sci Rep. 2020;10(1):2941.
- Ito A, Ito I, Inoue D, et al. The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: a multicentre, prospective study. Int J Infect Dis. 2020;92:228–233.
- Meyer Sauteur PM, Krautter S, Ambroggio L, et al. Improved diagnostics help to identify clinical features and biomarkers that predict Mycoplasma pneumoniae community-acquired pneumonia in children. Clin Infect Dis. 2020;71(7):1645–1654.
- Wallihan RG, Suarez NM, Cohen DM, et al. Molecular distance to health transcriptional score and disease severity in children hospitalized with community-acquired pneumonia. Front Cell Infect Microbiol. 2018;8:382.
- Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2017;65(2):183–190.
- Kamat IS, Ramachandran V, Eswaran H, et al. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(3):538–542.
- Bellmann-Weiler R, Ausserwinkler M, Kurz K, et al. Clinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia. J Clin Microbiol. 2010;48(5):1915–1917.
- Hangai S, Nannya Y, Kurokawa M. Role of procalcitonin and C-reactive protein for discrimination between tumor fever and infection in patients with hematological diseases. Leuk Lymphoma. 2015;56(4):910–914.
- Hahn WH, Song JH, Kim H, et al. Is procalcitonin to C-reactive protein ratio useful for the detection of late onset neonatal sepsis? J Matern Fetal Neonatal Med. 2018;31(6):822–826.
- Sprooten RTM, Lenaerts K, Braeken DCW, et al. Increased small intestinal permeability during severe acute exacerbations of COPD. Respiration. 2018;95(5):334–342.
- Koo BW, Oh AY, Ryu JH, et al. Effects of deep neuromuscular blockade on the stress response during laparoscopic gastrectomy randomized controlled trials. Sci Rep. 2019;9(1):12411.
- Marinovic T, Basic S, Romic D, et al. Dynamics of inflammatory factors expression in ischemic brain tissue injury. Neurol Int. 2019;11:8282.
- Schuetz P. Procalcitonin is useful for evaluating patients with ambiguous presentation and for early discontinuation of antibiotics in community-acquired pneumonia. Am J Respir Crit Care Med. 2020;201(6):744–745.
- Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379(3):236–249.
- Self WH, Wunderink RG, Jain S, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2018;66(10):1640–1641.
- Neeser OL, Vukajlovic T, Felder L, et al. A high C-reactive protein/procalcitonin ratio predicts Mycoplasma pneumoniae infection. Clin Chem Lab Med. 2019;57(10):1638–1646.